Gossamer Bio, Inc. — Q1 2023 Form 10-Q Summary
Business Context and Reporting Period
Gossamer Bio is a clinical-stage biopharmaceutical company focused on immunology, inflammation and oncology. The company is currently prioritizing seralutinib for pulmonary arterial hypertension and has discontinued development of GB5121 and other programs. This unaudited Form 10-Q covers the three months ended March 31, 2023, compared with the three months ended March 31, 2022.
Financial Position and Key Metrics
| Metric | Q1 2023 | Q1 2022 / Prior Period |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $37.8 million | $42.3 million |
| General and administrative expense | $10.1 million | $12.0 million |
| Total operating expenses | $47.9 million | $54.3 million |
| Net loss | $49.2 million | $57.8 million |
| Net loss per share | $0.52 | $0.76 |
| Net cash used in operating activities | $53.0 million | $53.5 million |
| Cash, cash equivalents and marketable securities | $201.9 million | Not stated on a comparable basis in the filing excerpt |
As of March 31, 2023, cash and cash equivalents were $65.2 million and marketable securities were $136.6 million. Total assets were $219.9 million, compared with $272.5 million at December 31, 2022. The company reported an accumulated deficit of $1.081 billion and stockholders’ deficit of $28.5 million, compared with stockholders’ equity of $12.1 million at year-end 2022.
Total debt was $216.8 million before distinguishing between the $20.8 million net Credit Facility balance and the $195.9 million net carrying amount of the 5.00% convertible senior notes due 2027. The Credit Facility matures January 1, 2025, with $21.3 million of principal scheduled to be repaid; the 2027 Notes have $200.0 million principal outstanding and mature June 1, 2027. The company was in compliance with applicable debt covenants at March 31, 2023.
Material Changes Versus the Prior Comparable Period
- Net loss improved by $8.6 million, or approximately 15%, primarily because operating expenses declined by $6.4 million and other expense decreased by $2.2 million.
- Research and development expense declined by $4.5 million. Spending on seralutinib increased by $5.8 million to $18.0 million, while spending on other terminated programs decreased by $11.3 million.
- General and administrative expense decreased by $1.9 million, primarily due to lower stock-based compensation, professional services and insurance costs.
- Cash used in operations was broadly stable at $53.0 million versus $53.5 million in Q1 2022.
- Cash and cash equivalents declined by $46.7 million during the quarter, partly reflecting the operating cash burn and $2.9 million of debt principal repayments.
- Weighted average shares outstanding increased to 94.9 million from 75.9 million, reflecting prior equity financing activity and other share issuances.
Guidance, Outlook, Risks and Unusual Items
Management expects to report results from the ongoing open-label extension of the Phase 2 TORREY study in mid-2023, initiate a Phase 3 seralutinib program in pulmonary arterial hypertension in the third quarter of 2023 and begin clinical development in pulmonary hypertension associated with interstitial lung disease in the first half of 2024.
The company expects to continue incurring significant operating losses and does not expect product revenue for the foreseeable future. Management believes existing cash, cash equivalents and marketable securities, together with available resources under the Credit Facility, are sufficient to fund operations for at least the next 12 months from the financial statement issuance date. However, the filing states that the Credit Facility’s remaining tranches were unavailable as of March 31, 2023, and additional capital will likely be required for longer-term operations and clinical development.
Key risks include clinical and regulatory failure or delay, uncertain development costs and timelines, inability to raise capital on acceptable terms, potential dilution from equity or convertible debt financing, debt and lease obligations, reliance on key personnel, intellectual property and licensing obligations, and the possibility that seralutinib will not achieve commercial approval or market acceptance.
The company disclosed contingent obligations under its seralutinib license, including up to $58.0 million of development and regulatory milestones, up to $45.0 million of commercial milestones, up to $190.0 million of sales milestones and tiered royalties. No additional milestone liability had been accrued as of March 31, 2023.
As a subsequent event, effective May 5, 2023, the company repriced 6.8 million eligible employee stock options to $1.36 per share, subject to specified conditions. Participating executive officers were required to cancel one-third of their eligible options; the chief executive officer did not participate.
Important Facts for Investors to Verify
- Progress, design, timing and funding requirements for the planned Phase 3 seralutinib program.
- Mid-2023 results from the TORREY open-label extension and their implications for regulatory strategy.
- Available liquidity relative to the expected clinical development cash burn and the company’s need for additional financing.
- Repayment schedule, covenant requirements and collateral provisions under the Credit Facility, including its January 2025 maturity.
- Potential dilution and incentive effects of the May 2023 stock option repricing.
- Remaining licensing milestones, royalties and other contingent payments related to seralutinib.
- Impact of the discontinued programs and the more-than-25% headcount reduction on operating capacity and execution risk.